Novel mch receptor antagonists
CA 2509042 A1 · Owner: Gillig, James Ronald · Inventors: Heinz, Lawrence Joseph; Kinnick, Michael Dean; Gillig, James Ronald
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1 Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt solvate, enantiomer or mixture of , diastereomers thereof useful in the treatment prevention or amelioration of , symptoms associated with obesity and Related Diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 3, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 3, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 3, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.